Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
10 December 2019 |
Main ID: |
EUCTR2010-019395-73-GB |
Date of registration:
|
17/06/2010 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyalgia rheumatica, followed by an open label phase to assess safety and long term efficacy
|
Scientific title:
|
A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyalgia rheumatica, followed by an open label phase to assess safety and long term efficacy |
Date of first enrolment:
|
20/09/2010 |
Target sample size:
|
30 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019395-73 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: yes Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Germany
|
Italy
|
United Kingdom
| | | | | |
Contacts
|
Name:
|
Medical Information Services
|
Address:
|
Frimley Business Park
GU16 7SR
Frimley, Camberley, Surrey
United Kingdom |
Telephone:
|
+44 01276698370 |
Email:
|
medinfo.uk@novartis.com |
Affiliation:
|
Novartis Pharmaceuticals UK Ltd |
|
Name:
|
Medical Information Services
|
Address:
|
Frimley Business Park
GU16 7SR
Frimley, Camberley, Surrey
United Kingdom |
Telephone:
|
+44 01276698370 |
Email:
|
medinfo.uk@novartis.com |
Affiliation:
|
Novartis Pharmaceuticals UK Ltd |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Patients must be aged =50 and =85 at time of consent
-Patients with newly diagnosed PMR as well as patients with a history of PMR or previous PMR episodes treated with corticosteroids. Corticosteroid treatment must not have been within 3 months of the screening visit.
- All female subjects must have negative pregnancy test results at screening (serum) and baseline (urine)
- Male subjects must be using two highly effective methods of contraception, comprising a barrier method condom or occlusive cap plus spermicide) plus ensure use by the female partner of a second method of contraception
- Patients must meet all of the following criteria (based on BSR guideline on PMR):
• Age = 50 and =85 years
• CRP > 1.0 mg/dl OR ESR > 30 mm/hr
• New bilateral shoulder and/or hip pain
• Early Morning stiffness > 60 min (at least 60 mins)
• Duration of illness > 1 week (at the time of initial diagnosis)
- Patient must be able to understand and communicate with the investigator, to understand and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed
- All patients receiving current vaccinations, especially influenza and pneumococcal as clinically indicated can be included. Patients should not receive any live vaccines (this includes nasal-spray flu vaccine) within 12 weeks before study entry and within 12 weeks of the last dose of AIN457 or ACZ885 (canakinumab)
- Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 17 to 35 kg/m2 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: - Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/mL)
- Men who are planning to initiate a pregnancy while enrolled in the study or for 4 months following completion of the study, or who are not willing to follow the restrictions in inclusion criterion 3. Male or female patients who plan to conceive during the time course of the study and 6 months post last infusion of AIN457/ACZ885 (canakinumab)
- Presence of rheumatoid arthritis or other inflammatory arthritic processes (features of GCA (Giant Cell Arthrtitis), spondyloarthropathies, Osteoarthritis, symptomatic shoulder capsulitis), connective tissue disease, drug-induced myopathies, chronic pain syndromes, as assessed by base line screening including TSH, CK, RF, CCP, ANA, serum protein electrophoresis, urinalysis, -Ongoing treatment with corticosteroids
- Previous exposure to methotrexate or other immune suppressive agent within 3 months prior to randomization.
- Previous exposure to AIN457 or ACZ885 (canakinumab) or other biologic targeting IL-17, IL-17 receptor, IL-1b or IL-1ß receptor, or use of any investigational drug and/or devices within 4 weeks prior to randomization or 5 half-lives of the investigational agent, whichever is longer and for any other limitation of pariticipation based on local regulations.
- Active systemic infections during the last two weeks (exception: common cold) prior to randomization or current use of antibiotics.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
polymyalgia rheumatica MedDRA version: 14.0
Level: PT
Classification code 10036099
Term: Polymyalgia rheumatica
System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
|
Intervention(s)
|
Product Code: AIN457 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: CAIN457A Other descriptive name: rhumAb to Il-17A (IgG1-k-class) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-
Trade Name: Ilaris Product Name: Ilaris Product Code: ACZ885 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CANAKINUMAB CAS Number: 914613-48-2 Current Sponsor code: ACZ885 Other descriptive name: Recombinant human monoclonal antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-
Trade Name: Prednison Hexal Product Name: Prednison Hexal Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISONE CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Secondary Objective: - To assess the time to partial clinical response, time to complete response and time to first flare in patients who respond to a single dose of AIN457 or ACZ885 (canakinumab) - To assess the effect of AIN457 and ACZ885 (canakinumab) on the number of flares over a 6 month period - To assess the effect of AIN457 and ACZ885 (canakinumab) on the cumulative and/or mean steroid dose over a 6 month period - To assess the safety and tolerability of AIN457 and ACZ885 (canakinumab) in patients with polymyalgia rheumatica - To characterize the PKs of AIN457 and ACZ885 (canakinumab) in patients with polymyalgia rheumatica - To compare the initial response to AIN457 and ACZ885 (canakinumab) with the response after redosing of AIN457 and ACZ885 (canakinumab) - To assess the effect on health-related quality of life (HAQ, SF-36) - To assess the potential for immunogenicity induced by ACZ885 (canakinumab) / AIN457 in PMR patients
|
Primary end point(s): The primary endpoint of the study is the PMR-AS on Day 15
|
Main Objective: - To assess the efficacy of a single dose of AIN457 after 2 weeks as measured by the polymyalgia rheumatica activity score. - To assess the efficacy of a single dose of ACZ885 (canakinumab) after 2 weeks as measured by the polymyalgia rheumatica activity score.
|
Secondary ID(s)
|
CPJMR0012201
|
Source(s) of Monetary Support
|
Novartis Pharma AG
|
Ethics review
|
Status: Approved
Approval date:
Contact:
|
|